Almotriptan frente a ergotamina mas cafeina en el tratamiento de las crisis agudas de migrana: analisis de coste-eficacia
Almotriptan vs. ergotamine plus caffeine for acute migraine treatment: a cost-efficacy analysis
Slof J, Lainez J M, Comas A, Heras J

Record Status
This is an economic evaluation that meets the criteria for inclusion on NHS EED.

Bibliographic details

PubMedID
19418289

Indexing Status
Subject indexing assigned by NLM

MeSH
Analgesics, Non-Narcotic /economics /therapeutic use; Caffeine /economics /therapeutic use; Cost-Benefit Analysis; Costs and Cost Analysis /economics; Ergotamine /economics /therapeutic use; Health Care Costs; Humans; Migraine Disorders /drug therapy /economics; Patient Satisfaction /economics; Quality of Life; Treatment Outcome; Tryptamines /economics /therapeutic use

AccessionNumber
22009101968

Date bibliographic record published
30/09/2009